Key result
LMWH matches or outperforms UFH for arterial thrombosis while being easier to administer.
Why the study?
The extension of low molecular weight heparin treatment to arterial diseases with prominent thrombosis has led to multiple clinical trials to evaluate its efficacy and safety.
Does low molecular weight heparin improve outcomes compared to unfractionated heparin in patients with arterial thrombosis?
Population
Patients with arterial disease including acute coronary syndromes, myocardial infarction, coronary and peripheral artery interventions, and stroke
Comparison
Low molecular weight heparin vs unfractionated heparin
Design
Review of clinical trials and meta-analyses
Authors
Loading...
Supports LMWH consideration over UFH in arterial thrombosis; leaves open need for updated RCTs in current ACS and stroke practice.
Does low molecular weight heparin improve outcomes compared to unfractionated heparin in patients with arterial thrombosis?
Low molecular weight heparin is an effective and easier-to-administer alternative to unfractionated heparin for arterial thrombosis indications such as acute coronary syndromes and stroke.
Nenci et al. (2000) conducted a review in Arterial thrombosis. Low molecular weight heparin (LMWH) vs. Unfractionated heparin was evaluated. Low molecular weight heparin has proved to be superior to or at least as effective as unfractionated heparin for arterial thrombosis indications, while being easier to administer.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: